GSK unveils Dragons' Den-style development boardScientists at GlaxoSmithKline will have to pitch their ideas to a "Dragons' Den Dragons' Den is a television programme that originated in Japan where the format is owned by Sony. The format, which now airs internationally, consists of entrepreneurs pitching their ideas to secure investment finance from business experts — the "Dragons". "-style development board with a $1bn (£500m) annual budget, including two venture capital bosses, a former NHS executive The National Health Service Executive (NHS Executive) was an integral part of the British Department of Health. It advised Ministers on the development of NHS policy and was responsible for the effective management of the NHS. The Executive ceased to exist on 1 April 2002. and the chief of a biotechnology firm, as part of an effort to improve the flow of new treatments emerging from the world's second largest drug company.
The board is part of a series of measures unveiled today by chief executive Andrew Witty Andrew Witty is the CEO-designate of GlaxoSmithKline (GSK). Currently serving GSK as President, Pharmaceuticals Europe, Witty will succeed CEO Dr. Jean-Pierre Garnier following his retirement in May 2008. References
1. during his maiden results presentation, aimed at restoring GSK GSK GlaxoSmithKline plc (pharmaceutical company)
GSK Glycogen Synthase Kinase
GSK Gruppentraining Sozialer Kompetenzen (Germany)
GSK Greenland Shark (FAO fish species code) to "predictable growth" amid the toughest business environment for the drugs industry in many years. The overhaul, he said, would lessen GSK's reliance on a handful of blockbuster drugs A blockbuster drug is a drug generating more than $1 billion of revenue for its owner each year. The search for blockbusters has been the foundation of the R&D strategy adopted by big pharmaceutical companies, but this looks set to change. , diversify the business geographically, particularly into emerging markets, and further cut costs.
"Today about 60% of our sales are accounted for by 10 drugs," he said. "What we want to do over time is broaden that concentration of our assets. I want to make sure this company doesn't have periods of boom and bust In economics, the term boom and bust refers to the movement of an economy through economic cycles. The Boom-Bust economic cycle
According to most economists, an economic boom is typically characterized by an increased level of economic output (GDP), a corresponding in R&D output. I want this company to be a sustained deliverer of product flow."
Additional investment will be directed toward the higher growth areas such as vaccines and consumer healthcare and over-the-counter medicines. He said potential customers, such as the NHS NHS
National Health Service
NHS (in Britain) National Health Service , would be brought in earlier in the drug development process to ensure that GSK's money was being invested in the right place.
In an effort to fire up innovation at the company, scientists will be based in smaller teams and will pitch three year business plans to secure backing, in the same way that a start-up might approach a venture capital firm. "We are looking to release energy and empower our scientists," Witty said.
The Drug Discovery Investment Board, led by Patrick Vallance, the company's head of drug discovery and including another six executives from inside the company, would provide a "very objective, disciplined decision-making" process. GSK would not reveal the identity of the four outsiders on the board.
It is also establishing a corporate venture fund, which will invest in start-ups that can be spun out of GSK and in early stage healthcare companies outside of the business.
The company reported a 2% decline in revenue for the second quarter to £5.87bn and a 3% drop in profits to £1.84bn; it expects a single digit decline in earnings over the full year. Sales of Avandia, its diabetes drug, fell 46% to £194m after GSK warned that the drug could increase the risk of heart attacks. A number of drugs were hit by generic competition, including the antidepressant antidepressant, any of a wide range of drugs used to treat psychic depression. They are given to elevate mood, counter suicidal thoughts, and increase the effectiveness of psychotherapy. Wellbutrin, down 27% and anti-nausea drug Zofran, down 49%.
In a demonstration of the company's strategy to expand its footprint around the world, it announced an alliance with South African pharmaceuticals firm Aspen aspen, in botany
aspen: see willow.
Aspen, city, United States
Aspen (ăs`pən), city (1990 pop. 5,049), alt. 7,850 ft (2,390 m), seat of Pitkin co., S central Colo. . Witty said as much as 50% of its new drugs could come from outside the business in the future, up from around 30% today, from investing in outside assets.
Witty said he understood the frustrations of shareholders in the business - GSK has been one of the worst performers in the FTSE FTSE
A company that specializes in index calculation. Although not part of a stock exchange, co-owners include the London Stock Exchange and the Financial Times.
The FTSE is similar to Standard & Poor's in the United States. 100 in recent years.
"There is a concern in the sector that this has become a low growth, high risk sector. So I believe a company like GSK has to face that head-on. There is absolutely no point dreaming about the 1990s - we've got to focus on what the world is going to be like in the next few years and that's really what we are starting to address. Let's take control of our own destiny and make sure we drive more growth and lower risk profile than perhaps is being perceived up to now."
GSK is pushing back its £12bn share buyback programme beyond its former deadline of July next year in order to ensure it has the flexibility to invest in the business.